featured
Addition of Docetaxel to Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials
Lancet Oncol 2023 Jul 01;24(7)783-797, CL Vale, DJ Fisher, PJ Godolphin, LH Rydzewska, JM Boher, S Burdett, YH Chen, NW Clarke, K Fizazi, G Gravis, ND James, G Liu, D Matheson, L Murphy, RE Oldroyd, MKB Parmar, E Rogozinska, P Sfumato, CJ Sweeney, MR Sydes, B Tombal, IR White, JF TierneyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.